Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-1 monoclonal antibody versus colchicine for gout flare prophylaxis during urate-lowering therapy
ChiCTR2600133686Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jun 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of genakumab, colchicine and febuxostat in gout (2 arms), sponsored by Beijing Hospital. Primary endpoint: Incidence of gout flares within 12 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
genakumabcolchicinefebuxostat
03
Conditions
gout
Beyond the preview
Go deeper on ChiCTR2600133686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133686.